Clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis
Both baricitinib and abatacept were effective in reducing disease activity in patients with RA. Baricitinib demonstrated potential advantages over abatacept in terms of early disease control, particularly in patients with high disease activity and without methotrexate use.
Authors
- Mochihito Suzuki (ORCID: https://orcid.org/0000-0003-4895-5028)
- Nobunori Takahashi (ORCID: https://orcid.org/0000-0001-6937-3567)
- Y. Hirano (ORCID: https://orcid.org/0000-0002-0422-8139)
- Tomonori Kobayakawa
- Toshihisa Kojima (ORCID: https://orcid.org/0000-0001-8497-0212)
- Yutaka Yoshioka
- Yasumori Sobue (ORCID: https://orcid.org/0000-0002-8936-4278)
- Masahiro Hanabayashi
- Kenya Terabe (ORCID: https://orcid.org/0000-0001-6469-1312)
- Shuji Asai (ORCID: https://orcid.org/0000-0002-4030-8793)
- Tatsuo Watanabe
- Shiro Imagama
- Yasuhide Kanayama (ORCID: https://orcid.org/0000-0002-2409-1619)
- Takefumi Kato
Institutions
- Aichi Medical University (JP)
- Ichinomiya Municipal City Hospital (JP)
- Handa City Hospital (JP)
- Japanese Red Cross Nagoya Daiichi Hospital (JP)
- National Hospital Organization (JP)
- Toyota Kosei Hospital (JP)
- Toyohashi Municipal Hospital (JP)
- Nagoya Medical Center (JP)
- Daido University (JP)
- Nagoya University (JP)
Publication Details
- Journal
- International Journal of Rheumatic Diseases
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1111/1756-185x.15414
- Citations
- 3
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Daiichi-Sankyo
- Eisai
- Astellas Pharma
- Chugai Pharmaceutical